JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265839

Human EXOC2 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

EXOC2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 2 bp insertion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

EXOC2_HUMAN, Exocyst complex component 2, Exocyst complex component Sec5, FLJ11026, SEC5, SEC5 like 1, SEC5L1, Sec5p

3 Images
Western blot - Human EXOC2 knockout HeLa cell line (AB265839)
  • WB

Lab

Western blot - Human EXOC2 knockout HeLa cell line (AB265839)

Lanes 1- 4 : Merged signal (red and green). Green - ab140620 observed at 104 kDa. Red - Anti-GAPDH antibody [6C5] - Loading Control (ab8245) observed at 37 kDa.

ab140620 was shown to react with EXOC2 in wild-type HeLa cells in western blot. The band observed in CRISPR/Cas9 edited cell line ab265839 (CRISPR/Cas9 edited cell lysate ab257944) lane below 104kDa may represent truncated forms and cleaved fragments. This has not been investigated further. Wild-type HeLa and EXOC2 CRISPR/Cas9 edited HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. ab140620 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4° at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-EXOC2 antibody [EPR9420] (<a href='/en-us/products/primary-antibodies/exoc2-antibody-epr9420-ab140620'>ab140620</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

EXOC2 CRISPR/Cas9 edited HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human EXOC2 knockout HeLa cell line (ab265839)

Lane 3:

SH-SY5Y cell lysate at 20 µg

Lane 4:

Daudi cell lysate at 20 µg

Predicted band size: 104 kDa

Observed band size: 104 kDa

false

Sanger Sequencing - Human EXOC2 knockout HeLa cell line (AB265839)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC2 knockout HeLa cell line (AB265839)

Allele-1 : 1 bp insertion in exon 3.

Sanger Sequencing - Human EXOC2 knockout HeLa cell line (AB265839)
  • Sanger seq

Unknown

Sanger Sequencing - Human EXOC2 knockout HeLa cell line (AB265839)

Allele-2 : 2 bp insertion in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 2 bp insertion in exon 3

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p>Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.</p>" } } }

Product details

We will provide viable cells that proliferate on revival.

Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265839-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265839-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265839 Human EXOC2 knockout HeLa cell line", "number":"AB265839-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265839-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265839-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265839 Human EXOC2 knockout HeLa cell line", "number":"AB265839-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265839-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265839 Human EXOC2 knockout HeLa cell line", "number":"AB265839-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265839-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265839 Human EXOC2 knockout HeLa cell line", "number":"AB265839-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
EXOC2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The exocyst complex component 2 also known as EXOC2 or SEC5 is an important protein involved in vesicle trafficking. EXOC2 has an estimated mass of around 105 kDa. It is widely expressed in various tissues highlighting its broad significance in cellular processes. Its primary role is to participate in the tethering of secretory vesicles to specific sites on the plasma membrane aiding in processes like cell migration and growth.
Biological function summary

EXOC2 acts as a fundamental part of the exocyst complex which comprises eight proteins. This complex orchestrates vesicle targeting and tethering during exocytosis a process essential for maintaining cell surface area and membrane protein composition. Unlike other vesicle trafficking complexes the exocyst shows significant specificity for certain vesicles and localization contributing to the precision of membrane-associated functions.

Pathways

EXOC2 joins key pathways like the insulin signaling pathway and the regulation of actin cytoskeleton. In the insulin signaling pathway EXOC2 integrates with components such as the protein Rab11 to mediate glucose transporter vesicle trafficking impacting glucose uptake. In the regulation of the actin cytoskeleton it interacts with actin-related proteins to influence cell shape and motility.

Connection with EXOC2 influences conditions such as cancer and diabetes. Abnormal EXOC2 expression links to various cancers often through disruptions in cellular trafficking and signal transduction. The interplay with diabetes arises partly through its role in insulin-mediated processes with proteins like Rab11 that affect glucose homeostasis. These associations highlight the potential for EXOC2 as a therapeutic target in these diseases.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com